Monograph
B01AD11 - Tenecteplase |
Not porphyrinogenic |
NP |
Rationale
Recombinant enzyme. No CYP-interactions.
Chemical description
Recombinant fibrinspecific plasminogen activator. Administered as infusion within 6 hours after heart infarction.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Metalyse · Metalyse 10.000 units, poeder en oplosmiddel voor oplossing voor injectie · Metalyse 5.000 units, poeder voor oplossing voor injectie · Metalyse 8.000 units, poeder en oplosmiddel voor oplossing voor injectieBelgium
Metalyse · Metalyse 10 000 U sol. inj. (pdr. + solv.) i.v. ser. préremplie flac. · Metalyse 5 000 U sol. inj. (pdr.) i.v. flac. · Metalyse 8 000 U sol. inj. (pdr. + solv.) i.v. ser. préremplie flac.United Kingdom
Metalyse · Metalyse 10,000unit powder and solvent for solution for injection vials · Metalyse 5,000unit powder for solution for injection vials · Metalyse 8,000unit powder and solvent for solution for injection vialsDenmark
MetalyseNorway
MetalysePoland
MetalyseLuxembourg
METALYSEIceland
MetalyseFinland
MetalyseLatvia
MetalyseSerbia
Metalyse · Metalyse®
© NAPOS 2024